Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients

August 7, 2023 updated by: University Hospital Ostrava

Bioelectrical Impedance Vector Analysis (BIVA) in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients

This prospective, blinded observational clinical study was aimed to determine the effect of hyperhydration and muscle loss measured by Bioelectrical impedance vector analysis (BIVA) on mortality. The aim was to compare hydratation parameters measured by BIVA: OHY, Extracellular Water (ECW) / Total Body Wate (TBW) and quadrant, vector length, phase angle (PA) with cumulative fluid balance (CFB) recording (input-output) in their ability in predicting mortality as the abilities of the prognostic markers PA (BIVA), Acute Physiology and Chronic Health Evaluation II (APACHE II - score) and presepsin (serum Cluster of Differentiation (CD) 14-ST). The investigators also compared BIVA nutritional indicators (SMM, fat) with BMI and laboratory parameters (albumin, prealbumin and C-reactive protein (CRP) inflammation parameters) in the prediction of mortality. An important goal was to evaluate the usability of the BIVA method in critically ill patients on extracorporeal circulation, to compare the impedance data of the extracorporeal membrane oxygenation (ECMO) and non-ECMO groups.

Study Overview

Detailed Description

Hyperhydration has a detrimental effect on mortality risk and morbidity, increases the risk of acute kidney failure, the need of renal replacement therapy (RRT), worsens recovery of renal functions and worsens lung injury (ALI), infectious complications, and causes prolonged artificial pulmonary ventilation (APV), the length of stay on Intensive care unit (ICU), and impairs wound healing.

Real-time assessment of fluid status and management of fluid administration in critically ill patients is challenging. Echocardiography can rapidly identify hemodynamic phenotypes, but it is rather intermittent than continuous methods and requires experienced and trained staff. Semi-invasive methods, based on stroke volume monitoring as the area under the arterial curve and variability of stroke volume variation (SVV) evaluate intravascular volume. However, these methods lack information about the interstitial fluid, part of extracellular water (ECW), or intracellular fluid water (ICW). This problem is partially solved by transpulmonary thermodilution with extravascular lung water (EVLW) measurement and lung ultrasound. Calculating the cumulative balance (CBF) is imprecise, especially in the area of fluid output for insensible losses or third-space fluid losses. Even more imprecise is the clinical assessment of peripheral edema and blood flow. And gold standard deuterium dilution methods for total body water (TBW) are not usable in daily practice in the ICU settings.

In addition to hyperhydration, the rapid loss of muscle tissue in critically ill patients has a negative impact on the course of the disease. Polyneuromyopathy affects up to 40 % of critically ill patients, patients in a severe catabolic state with an activated systemic inflammatory response (SIRS), with corticosteroid therapy, and immobilized on long-term artificial lung ventilation are at risk. Monitoring lean body mass, especially skeletal muscle mass (SMM), is still difficult. Anthropometric measurements and ultrasound measurements of the quadriceps muscles are not ideal because they are time-consuming and require well-trained staff. Some laboratory parameters such as albumin are likely to be influenced by inflammation (CRP), and hydration. Dual-energy X-ray absorptiometers (DEXA) using two different wavelengths of low-intensity X-rays give a relatively accurate picture of bone mass and soft tissues (fat-free mass, active mass, fat). However, repeated X-ray examination in immobilized critically ill patients is not the method of choice.

Bioelectrical impedance vector analysis (BIVA) is a simple, rapid, and noninvasive bedside technique, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes. It is thus able to measure body composition as skeletal muscle mass (SMM), and body cell mass (BCM), including total body water and extracellular water. And with the use of 50 frequencies of bioimpedance spectroscopy (BIS), it is possible to distinguish TBW, ECW, and from their different intracellular water, because only electric current with a frequency higher than 100 Hertz (Hz) passes through the cell membrane. However, the technique cannot distinguish between intravascular and interstitial volumes in the extracellular compartment. According to a number of studies, the results of bioimpedance parameters of body composition are comparable to DEXA. However, BIA overestimates the representation of muscle. An important parameter is the phase angle (PA), which detects a time delay of the passage of current through the cell membrane, i.e., a phase shift between the sinusoidal voltage and current waveforms. PA reflects BCM and serves as an important prognostic factor, with a normal value of 4-15°.

Of the laboratory markers, presepsin (PSEP) has prognostic significance. Presepsin, soluble Cluster of differentiation 14 (sCD14), is a glycoprotein expressed in the membranes of monocytes and macrophages in response to pathogen-associated molecular patterns (PAMPs: lipopolysaccharide, peptidoglycan) part of the bacterial wall or to other damage to cells - damage-associated molecular patterns (DAMPs). An interesting finding is its prognostic role, i.e. higher values in non-surviving patients, evaluated by a number of studies.

Study Type

Observational

Enrollment (Actual)

61

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Czech Republic
      • Ostrava, Czech Republic, Czechia, 70852
        • University Hospital Ostrava

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Critically ill adult patients admitted to 24 beds ICU of the University Hospital with the development of ARDS and the assumption of at least 7 days of artificial lung ventilation (medical, trauma, surgical patients) at the time of admission to the ICU.

Informed consent was obtained from the person legally responsible for the patient.

Description

Inclusion Criteria:

  • Patients with respiratory insufficiency, with the assumption of at least 7 days of artificial lung ventilation (medical, trauma, surgical patients)
  • Primary acute respiratory distress syndrome (ARDS) (pulmonary involvement): pneumonia, inhalation trauma, chest trauma (lung contusion), aspiration
  • Secondary ARDS (extrapulmonary): sepsis, shock states, acute pancreatitis, polytrauma, burns, non-cardiogenic shock, intoxication, TRALI (massive blood transfusion), drowning
  • Patients with acute exacerbation of chronic obstructive pulmonary disease (COPD)

Exclusion Criteria:

  • Patients with unfavorable prognosis
  • APACHE II ≥30
  • Metastatic malignancy
  • Conditions after cardiopulmonary resuscitation (KPCR) before admission
  • Cerebral edema
  • Brain trauma
  • Intracranial hypertension
  • Liver cirrhosis
  • A pre-existing neurodegenerative disease
  • Patients with pacemakers, defibrillators, pregnancy (conditions contraindications to use of bio-electrical impedance).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group of Patients who Survived (S)
The group is defined by the number of patients who survived.
BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
Cumulative balance is the sum of daily fluid balances during hospitalization.
Group of Patients who Died (D)
The group is defined by the number of patients who died.
BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
Cumulative balance is the sum of daily fluid balances during hospitalization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Mass (physique) - Bioelectrical impedance analysis (BIA)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Bioelectrical impedance analysis (BIA) comparison of skeletal muscle mass, body fat and body water (expressed in %) in patients hospitalized in the ICU.
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body Mass (physique) - Phase Angle (PA)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Assessment of the Phase angle (expressed in degrees) as a part of BIA in patients hospitalized in the ICU.
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body Mass (physique) - BIVA vector analysis (Cole Cole graf)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Assessment of the BIVA vector analysis (Cole Cole graf, expressed as a optimal curve dependence of resistance on reactance always at a specific frequency, divided into quadrants) in patients hospitalized in the ICU.
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Indicators of nutritional status (albumin, prealbumin)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Assesment of indicators of nutritional status (albumin, prealbumin in g/l) in serum of patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Indicator of inflammation (CRP)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Assesment of indicator of inflammation (C-reactive protein in mg/L) in serum of patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Indicator of inflammation - presepsin (PSEP)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Assesment of indicator of inflammation measurements (presepsin in ng/L) in serum of patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total body water (TBW)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Total body water measurements (in %) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Extracellular water (ECW)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Extracellular water measurements (in %) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Intracellular water (ICW)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Intracellular water measurements (in %) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Overhydration (OHY)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Overhydration measurements (in %) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Ratio ECW/TBW
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Ratio ECW/TBW measurements (in %) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Active body mass index (ATH)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Active body mass index measurements (in kg/m2) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body mass index (BMI)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body mass index measurements (in kg/m2) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body fat mass index (BFMI)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body fat mass index measurements (in kg/m2) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Fat-free mass index (FFMI)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Fat-free mass index measurements (in kg/m2) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Skeletal muscle mass (SMM)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Skeletal muscle mass measurements (in kg) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body cell mass (BCM)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Body cell mass measurements (in kg) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Basal metabolic rate (BMR)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Basal metabolic rate measurements (in kcal) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Nutric index (NI)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Nutric index measurements (in %) in patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Prediction marker (PM)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Prediction marker measurements in patients admitted to Intensive Care Unit (ICU). The mark value under 0,75 indicates normal condition, value over 0,86 means critical condition.
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Indicators of nutritional status (creatinine)
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Indicators of nutritional status measurements (creatinine in µmol/L) in serum of patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Level of 25-hydroxyvitamin D
Time Frame: The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Level of 25-hydroxyvitamin D measurements (in nmol/L) in serum of patients admitted to Intensive Care Unit (ICU).
The first within 48 hours of admission, the second one week after admission and third before transport from the ICU
Cumulative fluid balance (CFB)
Time Frame: Every 24 hours until patient´s transport from the ICU
Cumulative fluid balance daily measurements (in ml) in patients admitted to Intensive Care Unit (ICU).
Every 24 hours until patient´s transport from the ICU
Measurement of energy income
Time Frame: Every 24 hours until patient´s transport from the ICU
Measurement of daily energy income (in kcals) in patients admitted to Intensive Care Unit (ICU).
Every 24 hours until patient´s transport from the ICU
Measurement of protein income
Time Frame: Every 24 hours until patient´s transport from the ICU
Measurement of daily protein income (in g) in patients admitted to Intensive Care Unit (ICU).
Every 24 hours until patient´s transport from the ICU
Assessment of the presence of delirium (CAM-ICU test)
Time Frame: Every 24 hours until patient´s transport from the ICU
The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a simple and short test that enables continuous monitoring of the patients in conditions of ICU (measured as positive/negative).
Every 24 hours until patient´s transport from the ICU

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marcela Káňová, MD, Ph.D., University Hospital Ostrava

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2021

Primary Completion (Actual)

May 31, 2022

Study Completion (Actual)

May 31, 2022

Study Registration Dates

First Submitted

July 27, 2023

First Submitted That Met QC Criteria

August 7, 2023

First Posted (Actual)

August 15, 2023

Study Record Updates

Last Update Posted (Actual)

August 15, 2023

Last Update Submitted That Met QC Criteria

August 7, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to share individual participant data with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Septic Shock

Clinical Trials on Bioelectrical impedance vector analysis (BIVA)

Subscribe